Advanced search
Publication Cover
Current Medical Research and Opinion Volume 24, 2008 - Issue 3
Submit an article Journal homepage
100
Views
21
CrossRef citations to date
0
Altmetric
Original Article

Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study

José V. Lozano Serrería 2 Health Center, Valencia, SpainCorrespondence[email protected]
,
Vicente Pallarés Health Surveillance Center, Mutuas Union, Castellón, Spain
,
Luis Cea-Calvo Clinical Research Department, Merck Sharp & Dohme de España, Madrid, Spain
,
José L. Llisterri Ingeniero Joaquín Benlloch Health Center, Valencia, Spain
,
Cristina Fernández-Pérez Research Unit, Hospital Clínico San Carlos, Madrid, Spain
,
Juan C. Martí-Canales San Antonio Health Center, Motril, Spain
,
Jose Aznar Research Unit, Hospital Marina Alta, Denia, Spain
,
Vicente Gil-Guillén Clinic Department. Miguel Hernandez University, Alicante, Spain
,
Josep Redón Hypertension Clinic, Hospital Clínico Universitario, Valencia University, Spain.
& on behalf of the investigators of the PReV-ICTUS Study show all
Pages 659-670 | Accepted 28 Jan 2008, Published online: 24 Jan 2008

References

  • Kannel WB, Neaton JD, Wentworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFe (Multiple Risk Factor Intervention Trial). Am Heart J 1986;112:825–36
  • Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256: 2823–8
  • Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study. Arteriosclerosis 1988;8:207–11
  • Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2835–8
  • Sharrett AR, Patsch W, Sorlie PD, et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1994;14:1098–104
  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
  • Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9
  • Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7
  • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA 1998;279:1615–22
  • Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
  • Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipo-proteins: an idea whose time for testing is coming, part I. Circulation 2001;104:2376–83
  • Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11–20
  • Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–14
  • Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15
  • Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309–16
  • Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299–308
  • Kalantzi KJ, Milionis HJ, Mikhailidis DP, Goudevenos JA. Lipid lowering therapy in the elderly: is there a benefit? Curr Pharm Des 2006;12:3945–60
  • Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927–34
  • Farnier M, Garnier P, Yau C, et al. Prevalence of low HDL-cholesterol in patients with cardiovascular risk factors: The ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey. Int J Clin Pract 2006;60:1166–71
  • Patel JV, Kirby M, Hughes EA. The lipid audit: analysis of lipid management in two centres in Britain 2003. Br J Cardiol 2004;11: 2147
  • Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27:2444–9
  • Redon J, Cea-Calvo L, Lozano JV, et al. Blood pressure and estimated risk of stroke in the elderly population of Spain: The PREV-ICTUS study. Stroke 2007;38:1167–73
  • De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601–10
  • Brotons C, Royo-Bordonada MA, Alvarez-Sala L, et al. Adaptación Española de la Guia de Prevención Cardiovascular (I). [Spanish adaptation of the European Guide to Cardiovascular Prevention (I)]. Aten Primaria 2004;34:427–32
  • Instituto Nacional de Estadistica de España (Nacional Institute of Statistics of Spain). Cifras de Población. Available at: http://www.ine.es/inebase/cgi/um?M=%2Ft20%2Fe260&O=inebase&N=&L=. [Last accessed: 1 July 2005]
  • Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52
  • Milionis HJ, Rizos E, Goudevenos J, et al. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005;36:1372–6
  • Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997;17:1114–20
  • Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, et al. High-density vs. low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003;163:1549–54
  • Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627–37
  • Pfeffer MA, Sacks FM, Moyé LA, et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. J Am Coll Cardiol 1999;33:125–30
  • Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301–10
  • Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029–36
  • Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease. 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007;115: 450–8
  • Athyros VG, Kakafika AI, Papageorgiou AA, et al. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 2007;42:999–1009
  • Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med 2005;353:1252–60
  • Schaefer EJ, Asztalos BF. The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 2006;8:41–9
  • Insull W Jr, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004;164:1121–7
  • Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87:476–9
  • Birjmohun RS, Kastelein JJ, Poldermans D, et al. Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin 2007;23:1707–13
  • Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512–17
  • McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005;65:2719–40
  • Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007;81:849–57
  • Chapman MJ, Assmann G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253–68
  • Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. Clinicaltrials.gov, NCT00461630. Available at: http://www.clinicaltrials.gov/ct/show/NCT00461630?order=1 [Last accessed: 24 September 2007]
  • Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007;82:13

References

  • Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med 1997;102:35S–9
  • The burden of musculoskeletal conditions at the start of the new millennium: a report of a WHO scientific group. WHO Technical Report Series 919, World Health Organization, Geneva 2003. Health Technol Assess 2004;8: 1–78
  • Melton LJ, 3rd. Hip fractures: a worldwide problem today and tomorrow. Bone, 1993;14(Suppl 1):S1–8
  • Klift M van der, Laet CEDH de, McCloskey EV, et al. The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 2002;17:1051–6
  • Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992;13(Suppl 1):S7–15
  • Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998;8:611–7
  • SIGN (2003) Management of osteoporosis. Scottish Intercollegiate Guidelines Network. Available from http://www.sign.ac.uk [Last accessed 6 June 2007]
  • Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
  • Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118–24
  • Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med 2005;26:203–19
  • Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999–2006
  • Bischoff-Ferrari HA, Conzelmann M, Stahelin HB, et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? Osteoporos Int 2006;17:656–63
  • Staud R. Vitamin D: more than just affecting calcium and bone. Curr Rheumatol Rep 2005;7:356–64
  • Blake AJ, Morgan K, Bendall MJ, et al. Falls by elderly people at home: prevalence and associated factors. Age Ageing 1988;17:365–72
  • Cummings SR, Nevitt MC. Falls. N Engl J Med 1994;331:872–3
  • Drinka PJ. The importance of parathyroid hormone and vitamin D status in the treatment of osteoporosis and renal insufficiency. J Am Med Dir Assoc 2006;7:S5–9
  • Forli L, Halse J, Haug E, et al. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med 2004;256:56–62
  • Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004;80:1706S–9
  • Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4–8
  • Pasco JA, Henry MJ, Kotowicz MA, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res 2004;19:752–8
  • Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ 1996;155:1113–33
  • Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
  • Malavolta N, Pratelli L, Frigato M, et al. The relationship of vitamin D status to bone mineral density in an Italian population of postmenopausal women. Osteoporos Int 2005;16:1691–7
  • von Mühlen DG, Greendale GA, Garland CF, et al. Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. Osteoporos Int 2005;16:1721–6
  • Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996;51:145–7
  • Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1–160
  • Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
  • Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6:1–146
  • Slobbe LCJ, Kommer GJ, Smit JM Kosten van ziekten in Nederland 2003. Zorg voor euro’s [Costs of illness in the Netherlands 2003] Rijksinstituut voor Volksgezondheid en Milieu, RIVM; 2006
  • Osteoporose Tweede herziene richtlijn 2002. English summary published in Pols HA, Wittenberg J. CBO guideline “Osteoporosis” (second version). NTVG Ned Tijdschr Geneeskd 2002;146:1359–63.
  • Centraal Bureau voor de Statistiek [Central Office for Statistics]. Statline database, 2004. Available from http://www.cbs.nl [Last accessed 27 July 2007]
  • Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15 721–39
  • Government Actuary Department, 1999. Available from http://www.gad.gov.uk [Last accessed 14 July 2005]
  • Oden A, Dawson A, Dere W, et al. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998;8:599–603
  • Meyer HE, Tverdal A, Falch JA, Pedersen JI. Factors associated with mortality after hip fracture. Osteoporos Int 2000;11 228–32
  • Poor G, Atkinson EJ, O’Fallon WM, Melton III. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 1995;319:260–5
  • Todd CJ, Freeman C, Camilleri-Ferrante C, Laxton C, Muriel P, Palmer C et al. Anglian audit of hip fracture 2. Cambridge: Cambridge Health Services Research Group, University of Cambridge; 1999.
  • Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey [comment]. BMJ 1998;316 736–41
  • British National Formulary. Available from http://www.bnf.org/bnf/bnf/current/openat/index.htm [Last accessed 30 June 2005]
  • CvZ. (College voor Zorgverzekering) [Health Care Insurance Board]. Z-index. Available from http://www.medicijnkosten.nl [Last accessed 30 June 2005]
  • Curtis L, Netten A (Personal Social Services Research Unit). Unit costs of health and social care 2004. Available from http://www.pssru.ac.uk [14 July 2005]
  • Oostenbrink JB, Koopmanschap MA, Rutten FF. Manual for cost calculations: methods and recommended prices for economic evaluations in health care. Handleiding voor kostenberekeningen: methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor zorgverzekeringen, 2004
  • Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 2002;13:765–7
  • Stevenson MD, Oakley J, Chilcott JB. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 2004;24:89–100
  • Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004;8:iii,1–78
  • Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215–24
  • Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22
  • Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2007 [Epub ahead of print 13 Nov 2007]
  • Adachi J, Lynch N, Middelhoven H, et al. The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 2007;8:97 [Epub ahead of print 26 Sept 2007]
  • Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
  • Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686–94
  • Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023–31
  • Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383–91

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.